NCT07199530

Brief Summary

This observational study aims to investigate the association between elevated plasma D-dimer levels and the inflammatory response, as well as its impact on survival in adult patients with community-acquired pneumonia. the study participants will be subjected to sampling for D-dimer and calculation of CURB-65 score. this aims to find the relation between them

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 23, 2025

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

September 22, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 30, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

February 24, 2026

Status Verified

February 1, 2026

Enrollment Period

11 months

First QC Date

September 22, 2025

Last Update Submit

February 21, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • find the correlation between plasma D-dimer level and the severity of CAP

    measuring D-dimer level (\< 500 µg/L consider negative) on admission and correlating this with CAP severity.

    in 6 months

Study Arms (1)

only one group which will include patients with CAP to take a blood sample for D-dimer

Other: Blood Product

Interventions

blood sample for D-dimer

only one group which will include patients with CAP to take a blood sample for D-dimer

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

the participant is those patients with CAP WHO will meet the inclusion criteria previously mentioned

You may qualify if:

  • age ≥18 years
  • diagnosis of CAP based on clinical symptoms, laboratory findings, and radiological evidence.

You may not qualify if:

  • Patients with a history of coagulation disorders, cancer, or other chronic diseases, or refusal to participate.
  • patients who have any clinical or radiological signs suggesting COVID-19 pneumonia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain Shams University hospitals

Cairo, Egypt

RECRUITING

Central Study Contacts

Hieba Gamal Ezzelregal

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

September 22, 2025

First Posted

September 30, 2025

Study Start

March 23, 2025

Primary Completion

March 1, 2026

Study Completion

April 1, 2026

Last Updated

February 24, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

to save patients DATA

Locations